Analysts' ratings for Amgen AMGN over the last quarter vary from bullish to bearish, as provided by 11 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 2 | 4 | 4 | 1 | 0 |
Last 30D | 0 | 0 | 1 | 0 | 0 |
1M Ago | 2 | 2 | 1 | 0 | 0 |
2M Ago | 0 | 2 | 2 | 1 | 0 |
3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Amgen, revealing an average target of $349.0, a high estimate of $405.00, and a low estimate of $215.00. Observing a 3.48% increase, the current average has risen from the previous average price target of $337.25.
Exploring Analyst Ratings: An In-Depth Overview
The standing of Amgen among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Geoff Meacham | Citigroup | Announces | Neutral | $335.00 | - |
Michael Yee | Jefferies | Maintains | Buy | $380.00 | $380.00 |
Colin Bristow | UBS | Lowers | Neutral | $326.00 | $335.00 |
Olivia Brayer | Cantor Fitzgerald | Maintains | Overweight | $405.00 | $405.00 |
Yaron Weber | TD Cowen | Raises | Buy | $383.00 | $381.00 |
Aaron Gal | Bernstein | Announces | Outperform | $380.00 | - |
Robyn Karnauskas | Truist Securities | Raises | Hold | $333.00 | $320.00 |
Carter Gould | Barclays | Raises | Equal-Weight | $315.00 | $300.00 |
Olivia Brayer | Cantor Fitzgerald | Announces | Overweight | $405.00 | - |
Gregory Renza | RBC Capital | Maintains | Outperform | $362.00 | $362.00 |
Brian Skorney | Baird | Maintains | Underperform | $215.00 | $215.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Amgen. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Amgen compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Amgen's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Amgen's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Amgen analyst ratings.
Unveiling the Story Behind Amgen
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Amgen's Financial Performance
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Amgen's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 23.18%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Amgen's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 33.28% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Amgen's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 42.08%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Amgen's ROA stands out, surpassing industry averages. With an impressive ROA of 3.11%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Amgen's debt-to-equity ratio surpasses industry norms, standing at 8.02. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Analyst Ratings: Simplified
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.